Figure 6.
TPO and platelet counts. (A) Relationship of plasma thrombopoietin levels and peripheral platelet counts (× 109/L) during treatment with bortezomib twice weekly every 3 weeks for 8 cycles. The thrombopoietin level was measured in pg/mL and normalized to the day-1 level in order to combine the results from 5 patients. The platelet count represents the median platelet count for the same 5 patients in whom TPO was measured. (B) Similar data from a single patient receiving weekly bortezomib demonstrating less variance in the platelet count (× 109/L) and plasma TPO level (pg/mL).
